GILD - Gilead Sciences, Inc.
Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
As of May 15, 2026: spot at $129.79, ATM IV 27.5%, max pain $130.00, net GEX -$36.5M.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market Cap
- $165.19B
- P/E Ratio
- 17.93
- Beta
- 0.33
- 52-Week Range
- 97.86-157.29
- Dividend Yield
- $3.19
- CEO
- Daniel O'Day
- Employees
- 17,600
- IPO Date
- Jan 22, 1992
- Exchange
- NASDAQ
What GILD Looks Like to Options Traders Today
IV rank of 26.5% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); negative net gamma exposure (-$36.5M) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (0.009) is roughly flat across the wings.
What This Page Covers
The GILD overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked GILD overview questions
- What is GILD?
- GILD is the ticker symbol for Gilead Sciences, Inc., a listed security. Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. Listed on NASDAQ. GILD is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the GILD options snapshot look like today?
- As of May 15, 2026, the GILD options snapshot shows spot at $129.79, ATM IV 27.5%, IV rank 26.5%, max pain $130.00, net GEX -$36.5M, expected move 7.87%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are GILD's key statistics?
- Gilead Sciences, Inc. (GILD) carries a market capitalization of $165.19B, trailing P/E ratio of 17.93, beta of 0.33 relative to the broader market, 52-week range of 97.86-157.29. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does GILD belong to?
- Gilead Sciences, Inc. operates in the Healthcare sector, in the Drug Manufacturers - General industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare GILD's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the GILD data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).